N-propeptide type I collagen

a 24 kDa bone phosphoprotein; the amino propeptide extension of type I collagen alpha 1 chains
Also Known As:
aminoterminal telopeptide of type I collagen; collagen, N-propeptide type I-; propeptide-aI-I-collagen
Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results


1. Bolarin, D M: 1 article (09/2010)
2. Azinge, E C: 1 article (09/2010)
3. Toiviainen-Salo, Sanna: 1 article (01/2009)
4. Nousiainen, Elina: 1 article (01/2009)
5. Dunkel, Leo: 1 article (01/2009)
6. Mäkitie, Outi: 1 article (01/2009)
7. Kröger, Heikki: 1 article (01/2009)
8. Hero, Matti: 1 article (01/2009)
9. Ikeda, Noriko: 1 article (12/2002)
10. Miyoshi, Yasuo: 1 article (12/2002)

Related Diseases

1. Bone Resorption
01/01/2009 - "In letrozole-treated boys, the concentrations of the bone resorption marker urine aminoterminal telopeptide of type I collagen initially increased and thereafter slowly declined while the concentrations of the bone formation markers serum aminoterminal propeptide of type I collagen and serum alkaline phosphatase remained unchanged or slightly increased, respectively. "
12/05/2002 - "BMD of the lumbar supine (dual emission X-rays absorptiometry) and bone resorption (deoxypyridinoline, aminoterminal telopeptide of type I collagen, and carboxyterminal telopeptide of type I collagen) and formation (propeptide of type I procollagen, osteocalcin, and bone-specific alkaline phosphatase) markers were examined at baseline (before the surgery), 6 and 12 months after the start of tamoxifen treatment. "
04/01/1998 - "We compared here the effects of tamoxifen and toremifene on bone metabolism and density in 30 postmenopausal patients with breast cancer, who were randomized to receive tamoxifen (20 mg/day, n = 16) or toremifene (40 mg/day, n = 14) for 1 yr. Biochemical markers of bone resorption [urinary hydroxyproline, serum cross-linked carboxyterminal telopeptide of type I collagen, urinary cross-linked aminoterminal telopeptide of type I collagen (NTx)] and bone formation [serum bone-specific alkaline phosphatase, osteocalcin, and aminoterminal and carboxyterminal propeptide of type I procollagen] were assessed before treatment and at 6 and 12 months of the antiestrogen regimen. "
2. Breast Neoplasms (Breast Cancer)
3. Sickle Cell Anemia (Hemoglobin S Disease)

Related Drugs and Biologics

1. Collagen Type I (Type I Collagen)
2. Osteocalcin
3. Biological Markers (Surrogate Marker)
4. Alkaline Phosphatase
5. Tamoxifen
6. deoxypyridinoline
7. Estrogen Receptor Modulators (Antiestrogen)
8. Toremifene (Fareston)
9. Hydroxyproline (4 Hydroxyproline)
10. letrozole (Femara)